NDAORALTABLET, EXTENDED RELEASE
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20
Clinical Trials (5)
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
Started Nov 2023
203 enrolled
Plaque Psoriasis
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Started Oct 2023
51 enrolled
Plaque Psoriasis
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Started Mar 2023
48 enrolled
Behçet's DiseaseJuvenile Psoriatic Arthritis
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
Started Jan 2023
17 enrolled
Plaque Psoriasis
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Started Sep 2022
1,500 enrolled
Psoriasis
Loss of Exclusivity
LOE Date
May 27, 2042
197 months away
Patent Expiry
May 27, 2042
Exclusivity Expiry
Jan 20, 2027